-+ 0.00%
-+ 0.00%
-+ 0.00%
Evaxion swings to Q3 2026 net loss of USD 3.54 million year over year
Share
Listen to the news
Evaxion swings to Q3 2026 net loss of USD 3.54 million year over year
  • Evaxion swung to a third-quarter 2026 net loss of USD 3.54 million from a year-earlier profit of USD 4.62 million.
  • Revenue fell to nil from USD 7.49 million a year earlier, when results included out-licensing revenue from EVX-B3.
  • Cash totaled USD 13.3 million at September 30, 2026, with cash runway extended toward the end of 2027.
  • The company is refocusing its strategy on immuno-oncology, prioritizing cancer vaccine development and partnerships.
  • An application for a phase 1 trial of off-the-shelf cancer vaccine EVX-04 remains on track for submission before year-end 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190700PRIMZONEFULLFEED1001304474) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending